

# Global X Genomics & Biotechnology UCITS ETF (GNOM)

## FUND OBJECTIVE

The Global X Genomics & Biotechnology UCITS ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics V2 Index.

For informational purposes only. This document should be used to highlight some of the criteria to be used by index provider when publishing index constituents and is not comprehensive.\*

As of 2 Nov 2021

Index Provider: SOLACTIVE AG



## KEY FEATURES



High Growth Potential



Targeted Exposure



ETF Efficiency

## SOLACTIVE GENOMICS V2 INDEX

### SELECTION

- The index is designed to track the performance of companies that have or are expected to have significant exposure to the field of Genomics by using a natural language processing (NLP) algorithm that evaluates publicly available information such as financial websites, search engines, and company publications.
- Companies are first ranked according to the reference frequency of the index theme specific keywords (“Index Score”).
- Companies are then screened based on revenue exposure to one of the following Genomics related business operations:
  - Gene editing
  - Genomic sequencing
  - Development and testing of genetic medicine/therapies
  - Computational genomics and genetic diagnostics
- Companies that derive at least 50% of revenue from the above Genomics related business operations above are eligible for the index. Companies that are not confirmed based on the 50% of revenue screen but that are classified as “Biotechnology” by FactSet are further reviewed and analyzed based on Research and Development (R&D) expenditures, product pipeline, and operating business segments. Only those Biotechnology companies with exposure to the Genomics related business activities are eligible for the index.
- The remaining eligible companies are ranked by their Index Scores, and the 40 highest ranking companies constitute the final index.

### SELECTION POOL

- Primary listing is in one of the Developed Countries, as defined by the Solactive Country Classification, or
- American Depository Receipts (ADRs) that have primary listing in Emerging Countries.
- Market capitalization of at least USD 200 million for new index constituents (existing constituents will remain in the index unless market capitalization falls below USD 160 million)
- Free float percentage of total shares outstanding of at least 10% or a minimum free float market capitalization of USD 1 billion
- Average daily trading volume in the last six months of at least USD 2,000,000 for new index constituents (existing constituents will remain in the index unless average daily trading volume falls below USD 1,400,000)
- Classified under the Economy “Healthcare” in the FactSet Industries and Economic Sectors Classification.

### WEIGHTING SCHEME

- Index components are weighted according to Free Float Market Capitalization with the following constraints applied at each semi-annual rebalance:
  - Each component is subject to maximum weight of 4% and minimum weight of 0.3%.
  - Any component with a market capitalization larger than \$50 billion USD is capped at 2%; for constituents that have been included in the index with the capping applied, the capping remains effective unless the company's market capitalization drops below \$40 billion USD.



## REBALANCES/REVIEWS

- The index follows a semi-annual reconstitution schedule. Adjustments are made on the second Friday in May and November.
- An existing index constituent is only excluded if it does not have a positive Index Score or it generates less than 50% of its revenues from Genomics related business operations and/or is no longer classified as "Biotechnology".
- A new company is added only if it passes all selection criteria and ranks in the top 10 in the Index Score ranking.

For more information on the Index, please visit [Solactive's website](#).

\* For the complete and current index methodology please refer to the index provider's website. This summary document is accurate as of the time of its publication and Global X does not guarantee that it is current at any point thereafter.

The selection of the index constituents and their weighting is made by the index provider at its sole discretion.

Solactive AG indexes have been licensed for use by Global X Management Company LLC. Solactive AG does not make any representations regarding the advisability of investing in Global X UCITS ETFs. One cannot invest directly in an index.

### United Kingdom

Issued by Global X Management Company (UK) Limited, 123 Buckingham Palace Road, London, SW1W 9SH, which is authorised and regulated in the UK by the Financial Conduct Authority. Information about us can be found on the Financial Services Register (register number 965081).

Capital at risk: The value of an investment in ETFs may go down as well as up and past performance is not a reliable indicator of future performance.

The data displayed provides summary information. Investment should be made on the basis of the relevant Prospectus & KIID which is available from the manager or the Global X website, [www.globalxetfs.eu](http://www.globalxetfs.eu). In respect of the product(s) mentioned this document is only intended for information purposes and does not constitute investment advice or an offer to sell or a solicitation of an offer to buy the securities described within.. Investing in Exchange Traded Products "ETPs" may not be suitable for all types of investors as they carry a high degree of risk. You may lose all of your initial investment. Only speculate with money you can afford to lose. Changes in exchange rates may also cause your investment to go up or down in value. Tax treatment depends on the individual circumstances of each investor and may be subject to change in the future. Please ensure that you fully understand the risks involved. If in any doubt, please seek independent financial advice. Investors should refer to the section entitled "Risk Factors" in the relevant prospectus for further details of these and other risks associated with an investment in the securities offered by the Issuer.

This material has been approved as a financial promotion, for the purposes of section 21 of the Financial Services Market Act 2000 (FSMA), by Resolution Compliance Limited which is authorised and regulated by the Financial Conduct Authority (FRN:574048).

### Switzerland

The representative in Switzerland is 1741 Fund Solutions Ltd, Burggraben 16, CH-9000 St. Gallen. The paying agent in Switzerland is Tellico Ltd, Bahnhofstrasse 4, CH-6430 Schwyz. The prospectus, the Key Investor Information Document (KIID), the ICAV's instrument of incorporation and as well as the annual and semi-annual reports may be obtained free of charge from the representative. In respect of the units offered in Switzerland, the place of performance is the registered office of the representative.

The place of jurisdiction is at the registered office of the representative or at the registered office or place of residence of the investor.